BioSpace News Archive

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the fourth quarter of 2020 and provided an update on recent developments.

Neuronetics, Inc. announced that clinical data from NeuroStar Outcomes Registry comparing outcomes with NeuroStar’s Standard TMS protocol and its shorter, Dash protocol has been published in Brain Stimulation and is available online now.

NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today that it has successfully met the first performance milestone in the distribution and development agreement with Zimmer Biomet

Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies, today announced that it plans to release financial results for the fourth quarter and year ended December 31, 2020

StratusTM Medical, a company focused on advancing radiofrequency ablation (RFA) treatment for chronic pain, announced today that the United States Patent and Trademark Office has granted a third U.S. patent related to its Nimbus® RF Multitined Expandable Electrode.

Phyla announced the release of results from a clinical study for its Phortify Probiotic Serum containing the brand’s flagship probiotic live phage.

Biotechnology company signs CMO to produce metric tons of rare cannabinoids for nutraceutical, skincare, and other consumer health and wellness products

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will present at the upcoming H.C. Wainwright Global Life Sciences Conference. Evofem’s CEO, Saundra Pelletier , will provide an update on the commercialization of its non-hormonal, use-it-only-when-you-need-it birth control method,

Full Year Sales Up 60.9% - Fourth Quarter Sales Up 90.5% - Full Year Subscriptions Up 25% 2021 Outlook Revenue Raised, Key Strategic Initiatives Reaffirmed

PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, announced today that the Risk Underlying Rural Areas Longitudinal Study (RURAL) has selected PixCell’s novel miniaturized, portable hematology analyzer, HemoScreen™